Projects
Non-invasive prediction of immunotherapy response for lung cancer patients Ghent University
An increasing number of patients with, amongst others, non-small cell lung cancer (NSCLC), melanoma and bladder cancer, undergoes treatment with immune checkpoint inhibitors. Globally speaking, 20 to 45% of patients will respond to this class of medicines in mono- or combination therapy. Nevertheless, existing predictive biomarkers cannot accurately separate non-responders from responders and require invasive tumor tissue sampling. Lately, ...
Artificial Intelligence/Machine Learning (AI/ML) -driven dissection of the microbiome’s multi-factorial impact on colorectal cancer (CRC) immune-landscape to guide clinical immunotherapy. KU Leuven
Deciphering and targeting novel immune-checkpoints engaged by dying cancer cells, to improve anti-cancer immunotherapy KU Leuven
Revealing the cancer cell-intrinsic immunotherapy targets in glioblastoma using reverse translational approaches. KU Leuven
Inducing neoantigens with cold atmospheric plasma to improve cancer immunotherapy. University of Antwerp
Immunogenic cancer cell death: From molecular determinants and immune responses to pre-clinical immunotherapy. KU Leuven
Developing a novel synergistic approach of chemotherapy and immunotherapy to enhance the anti-tumor immune response in non-small cell lung cancer. University of Antwerp
Expression of the metabolite transporter SLC4A4 in pancreatic cancer cells promotes immuneescape and resistance to immunotherapy KU Leuven
Exploring co-encapsulation of antihistamines and immune checkpoint siRNAs in lipid nanoparticles for cancer immunotherapy. Ghent University
Our group recently showed that cationic amphiphilic drugs (CADs) can complex nucleic acids in lipid nanoparticles (LNPs) for drug combination therapy. This project aims to evaluate this CAD-LNP platform in cancer immunotherapy. Immune checkpoint blockade (ICB), e.g. via PD-L1 antibodies, has demonstrated clinical efficacy, but is hampered by immune-related off-target effects following systemic exposure and low response rates due to an ...